Intracoronary Injection of Autologous CD34+ Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance—A Randomized, Open-Label, Controlled Phase II Clinical Trial

Intracoronary Injection of Autologous CD34+ Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance—A Randomized, Open-Label, Controlled Phase II Clinical Trial

This phase II randomized controlled trial tested whether intracoronary autologous CD34+ cell therapy could further improve left ventricular (LV) systolic function in patients with diffuse coronary artery disease (CAD) with relatively preserved LV ejection fraction (defined as LVEF >40%) unsuitabl...

Full description

Bibliographic Details
Main Authors: Pei-Hsun Sung, Yi-Chen Li, Mel S. Lee, Hao-Yi Hsiao, Ming-Chun Ma, Sung-Nan Pei, Hsin-Ju Chiang, Fan-Yen Lee, Hon-Kan Yip
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Journal of Clinical Medicine
Subjects:
diffuse coronary artery disease
angiogenesis
CD34+ cells
preserved LVEF
heart failure
angina
Online Access:https://www.mdpi.com/2077-0383/9/4/1043

Similar Items

Similar Items